Highest-materiality recent filing
ImageneBio Q1 net loss $10.6M; cash $117.2M, raised $30M in April private placement
Net loss of $10.6M for Q1 2026, vs $9.1M in Q1 2025; R&D $6.0M, G&A $6.1M.
Gross proceeds of ~$30M from sale of pre-funded warrants for 5.77M shares at $5.199 each.
ImageneBio reports Q4 2025 net loss $6.9M; cash $135.3M; Phase 2b ADAPTIVE on track for 2027
Cash, equivalents and marketable securities: $135.3M at Dec 31, 2025 vs $12.1M at Dec 31, 2024, after merger and $75M private placement.
Imagenebio CMO Yufang Lu resigns effective Dec 31, 2025; search underway
Yufang Lu, M.D., Ph.D., Chief Medical Officer, resigned effective December 31, 2025.
ImageneBio reports Q3 net loss of $24.8M; advances Phase 2b AD trial with protocol amendment
Cash, equivalents, and marketable securities $142.6M as of Sep 30, 2025; net loss $24.8M for Q3 2025 vs $3.2M in Q3 2024; R&D $15.6M, G&A $11.0M.
CFO Jotin Marango resigns effective Oct 20; search for replacement begun
CFO Jotin Marango, M.D., Ph.D., resigned effective October 20, 2025.
ImageneBio files Inmagene pre-merger financials: $13.7M loss, going concern, $6M cash
Inmagene net loss of $7.6M in Q2 2025 and $13.7M in first half 2025; accumulated deficit $197.5M.
Merger closed July 25: Ikena acquired Inmagene, name changed to ImageneBio, ticker changes to IMA on Nasdaq Capital Market.
Ikena Oncology completes merger with Inmagene, becomes ImageneBio, raises $75M private placement
Merger closed July 25, 2025; combined company renamed ImageneBio, Inc., trading on Nasdaq under IMA starting July 28.
Ikena stockholders approve Inmagene merger; 1:12 reverse split; combined co. to trade as IMA
All 7 proposals approved including merger issuance of IKNA shares >20% and reverse split.
ISS and Glass Lewis recommend Ikena stockholders vote FOR Inmagene merger
Institutional Shareholder Services (ISS) and Glass Lewis recommend voting FOR share issuance related to merger with Inmagene.
Ikena Oncology merges with Inmagene; Inmagene shareholders to own 55.6% of combined co.
Pre-PIPE, Inmagene shareholders own ~55.6%, Ikena ~44.4% of combined company.
Ikena Oncology discontinues IK-930, cuts workforce 53%, explores strategic options
Discontinued IK-930 (TEAD1 inhibitor) clinical development; winddown activities began.
Ikena Oncology appoints Caroline Germa as CMO; Sergio Santillana resigns
Sergio Santillana resigns as CMO effective Feb 29, 2024; will consult through Dec 31, 2024 at $500/hour.
Ikena Oncology cuts workforce 35%, focuses on IK-930/595; BMS declines opt-in on two programs
Workforce reduction of ~35% (approx. 20 employees) to focus on clinical programs IK-930 and IK-595.
Ikena reports Q3 cash $196.9M, IK-930 shows stable disease in all 7 EHE patients
Q3 2023 cash, cash equivalents and marketable securities of $196.9M; runway into 2026.
Stockholders approve stock issuance on conversion of Series A Preferred for Pionyr acquisition
Special meeting on October 11, 2023; 37,464,898 shares outstanding.
Ikena Oncology acquires Pionyr in all-stock deal, receives ~$43M net cash
Ikena issued 1.8M common shares and 4.2M Series A convertible preferred shares at $7.15/share for all of Pionyr.
Ikena raises ~$40M in equity offering; Q1 cash $137.8M; runway to 2026
Underwritten offering of 6.11M shares at $6.55/share for gross proceeds of ~$40M; closing expected May 17, 2023.
IK-930 selectively inhibits TEAD1 with equivalent antitumor activity to panTEAD inhibitors but no renal toxicity in monkeys at any tested dose.
Ikena Oncology nominates IK-595 as first RAS pathway candidate; IND targeted H2 2023
IK-595: MEK-RAF complex inhibitor traps MEK & RAF in inactive complex, aims to avoid resistance.
IK-175 combo with nivolumab: 20% ORR, 40% DCR in heavily pretreated urothelial carcinoma patients who progressed on checkpoint inhibitors.
IK-175 (AHR antagonist) Phase 1b trial (NCT04200963) combination with nivolumab expansion cohort advanced to stage two in April 2022.
Ikena Oncology COO & EVP of Finance Douglas Carlson resigns; interim PAA named
Douglas R. Carlson resigns as COO and EVP of Finance, effective Feb 18, 2022, to pursue other opportunities.
On July 8, 2024, the Board of Directors (the “Board”) of Ikena Oncology, Inc. (the “Company”) appointed Jotin Marango, M.D., Ph.D. to serve as the Company’s Chief Operating Officer, effective as of July 15, 2024 (the “Effective Date”), in addition to his role as the Company’s Chief Financial Officer and Head of Corporate Development.
On February 20, 2024, Sergio Santillana, M.D., M.Sc., MBA, notified Ikena Oncology, Inc. (the “Company”) of his decision to resign from his role at the Company as Chief Medical Officer effective as of February 29, 2024, with his last day of employment being March 5, 2024 (the “Departure Date”).
On December 15, 2022, Ronald Renaud notified the Company of his intent to resign from the Company’s Board and from his positions as Chairman of the Board, Chair of the Audit Committee of the Board and member of the Compensation Committee of the Board, effective December 15, 2022.
On December 15, 2022, Mr. Hughes filled the vacated positions on the committees of the Board and became the Chairman of the Board
appoint Jotin Marango, M.D., Ph.D. as Chief Financial Officer, Head of Corporate Development, effective April 25, 2022
On February 18, 2022, the Board of Directors (the “Board”) of Ikena Oncology, Inc. (the “Company”) unanimously appointed Francisco Olivera as the acting Principal Accounting Officer of the Company.
This appointment has been made in connection with the effectiveness of the resignation of Douglas R. Carlson, as previously disclosed on January 28, 2022
Francisco Oliveira, the Head of Finance and Administration since 2019, will serve as Principal Accounting Officer and report directly to the Company’s Chief Executive Officer, Mark Manfredi, on an interim basis effective as of Mr. Carlson’s departure, while a formal search process to appoint a new Chief Financial Officer is conducted.
On January 28, 2022, Douglas R. Carlson informed Ikena Oncology, Inc. (the “Company”) of his intent to resign as Chief Operating Officer and Executive Vice President of Finance of the Company to pursue other professional opportunities with broader responsibility.
On January 21, 2022, the Board of Directors (the “Board”) of Ikena Oncology, Inc. (the “Company”) unanimously appointed Dr. Richard Wooster to fill a newly created vacancy on the Board resulting from an increase in the size of the Board from seven (7) to eight (8) directors.
Max materiality 0.95 · Median 0.55 · Most common event other_material